Amylyx Drug Reduces Low Blood Sugar Episodes in Bariatric Surgery Patients

Amylyx Pharmaceuticals announced positive results from a pivotal clinical trial showing that its experimental drug significantly reduced the frequency of severe hypoglycemia (low blood sugar) episodes in patients who have undergone bariatric surgery. The company reported that the Phase 2/3 study evaluating the drug's effect on postprandial (after-meal) hypoglycemia—a complication that severely impacts quality of life in this patient population—yielded favorable data. In the study, patients receiving the drug experienced a statistically significant reduction in hypoglycemic episodes compared to the placebo group. These findings are seen as a potential new treatment option for managing this challenging condition, which can occur after obesity surgeries such as gastric bypass and is characterized by abnormally low blood sugar levels following meals. Amylyx management stated that the results confirm the drug's potential in this indication and provide a basis for discussions with regulatory authorities. The company plans to present the full data at upcoming medical conferences and initiate the necessary steps for drug approval. Experts note that this outcome is promising for patients suffering from post-surgical hypoglycemia who currently have limited treatment options, but they emphasize that the drug's efficacy and safety need to be confirmed in longer-term studies across broader patient groups. Amylyx's progress in this area is also strategically important for the company's efforts to diversify its existing product portfolio. This is not investment advice.